Over half of ulcerative colitis patients found relief with longer treatment

Many people with ulcerative colitis feel stuck when standard treatments stop working. A new review of two major trials shows that extending treatment with risankizumab can help. This approach gave hope to patients who had not achieved a clinical response after 12 weeks of initial therapy. The study looked at 209 people who did not get better with the first round of injections or IV drops. These patients received an additional 12 weeks of risankizumab at different doses. Over 50 percent of these initial nonresponders achieved a clinical response during this extended phase. This means their symptoms improved enough to be considered a positive outcome by doctors. The data comes from a Phase 3 randomized controlled trial, which is considered the gold standard for proving a treatment works. The researchers compared different ways of giving the drug to find the best option for people who need more help.